Answers are grounded in this paper and cite their sources.
The delivery of extrahepatic lipid nanoparticles (LNP) is a significant challenge in nanomedicine, as it faces complex biological barriers, a lack of understanding of the underlying mechanisms and a strong liver-biased biodistribution. The development of predictive models has been boosted by the recent progress in artificial intelligence (AI) and machine learning, but most models are still based on a small, heterogeneous datasets and are not interpretable. In this context, explainable AI (XAI) offers a useful tool to shift the focus from black-box prediction to pinpointing the role that formulation variables such as lipid chemistry, PEG density, particle size, and manufacturing parameters play in organ-specific delivery outcomes. Interpretation of model behavior via methods including SHAP, LIME, partial dependence analysis and counterfactual reasoning can be used to generate hypotheses and inform rational design of LNP systems. This review focuses on the liver, spleen, lung and bone marrow targeting possibilities for organ-selective design rules, which can be uncovered by XAI. It also highlights critical translational obstacles, such as dataset fragmentation, lack of standardization, missing metadata and the limited extrahepatic delivery data. A roadmap for the development of an XAI-guided LNP is proposed, which involves standardized multimodal data, multimodal AI models, explainability tools, iterative experiments for validation, and regulatory considerations.
No takes yet. Share an insight, caveat, or question.
Farghama et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: